Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 29 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer

  • Hong Wang1
  • Lazar Vujanovic2
  • Seungwon Kim3
  • Aditi Kulkarni2
  • Heath Skinner4
  • Simon Chiosea3
  • Dan P Zandberg5
  • Housaiyin Li2
  • Steven Chinn5
  • Pragati Upadhyay6
  • Matthew Spector5
  • Henry Thorpe5
6 more authors
  • Kevin J Contrera5
  • Shaum Sridharan7
  • Zahra Kelly1
  • Brand Matthias5
  • Jose P Zevallos1
  • Robert L Ferris8
8 affiliations
  1. 1University of Pittsburgh, Pittsburgh, PA, USA
  2. 22University of Pittsburgh, Pittsburgh, PA, USA
  3. 31University of Pittsburgh, Pittsburgh, PA, USA
  4. 42UPMC Hillman Cancer Center, Pittsburgh, PA, USA
  5. 5UPMC Hillman Cancer Center, Pittsburgh, PA, USA
  6. 64UPMC Hillman Cancer Center, Pittsburgh, PA, USA
  7. 7University of Pittsburgh Medical Center, Pittsburgh, PA, USA
  8. 8The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Open at sourcePDFDOICite

Related

  1. Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
    Ayana T. Ruffin, Crystal L. Mallow, Brian M. Olson +24
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. Safety profiles of current and emerging neoadjuvant immune-modulatory and combination strategies in borderline resectable stage III non-small cell lung cancer: a narrative review
    Nabih Berjaoui, Yee Tung (Ruby) Siu, Andrea Bille +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
  3. 473 Effect of nivolumab with or without relatlimab after stereotactic body radiotherapy in patients with advanced esophagogastric cancer
    Chen Hu, Valsamo Anagnostou, Gavin Pereira +11
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  4. Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery
    Georgina Long, Charlie Garnett-Benson, Sonia Dolfi +23
    Future OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyHAL
  5. Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
    Apostolia M. Tsimberidou, Christopher R. Cabanski, Alexandra Drakaki +15
    Science advancesPeer-reviewedCC BYFull textOncologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{wang2026phase,
  title = {{484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer}},
  author = {Hong Wang and Lazar Vujanovic and Seungwon Kim and Aditi Kulkarni and Heath Skinner and Simon Chiosea and Dan P Zandberg and Housaiyin Li and Steven Chinn and Pragati Upadhyay and Matthew Spector and Henry Thorpe and Kevin J Contrera and Shaum Sridharan and Zahra Kelly and Brand Matthias and Jose P Zevallos and Robert L Ferris},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0484},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0484},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer
AU  - Hong Wang
AU  - Lazar Vujanovic
AU  - Seungwon Kim
AU  - Aditi Kulkarni
AU  - Heath Skinner
AU  - Simon Chiosea
AU  - Dan P Zandberg
AU  - Housaiyin Li
AU  - Steven Chinn
AU  - Pragati Upadhyay
AU  - Matthew Spector
AU  - Henry Thorpe
AU  - Kevin J Contrera
AU  - Shaum Sridharan
AU  - Zahra Kelly
AU  - Brand Matthias
AU  - Jose P Zevallos
AU  - Robert L Ferris
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0484
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0484
SN  - 2051-1426
ER  -